Peer Reviewed Publication: A peer reviewed article titled “Pentosan Polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: Insight into structural requirements for binding” was published in the online journal Thrombosis and Haemostasis in April 2022. The publication is a result of work on the effectiveness of PPS performed by the Ronzoni Institute as part of the bene pharmaChem and Paradigm research collaboration agreement (ASX release 31/03/21). The in vitro study demonstrated that PPS inhibited the uptake of SARS- CoV2 in the established Vero cells that are used as an industry model. Mechanistically, PPS demonstrated binding to the S1 receptor binding domain (RBD) on SARS-CoV2 which led to the inhibition of viral uptake and viral propagation by Vero cells. These observations suggest that PPS is a potential novel inhibitor of SARS-CoV2 infection and transmission.
The peer reviewed publication can be viewed at: https://www.thieme- connect.com/products/ejournals/html/10.1055/a-1807-0168
- Forums
- ASX - By Stock
- PAR
- Ann: Quarterly Update and Appendix 4C - quarterly
Ann: Quarterly Update and Appendix 4C - quarterly, page-2
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $104.9M |
Open | High | Low | Value | Volume |
31.0¢ | 31.5¢ | 29.0¢ | $161.3K | 527.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 10756 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 62010 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 10756 | 0.300 |
1 | 99965 | 0.295 |
5 | 87991 | 0.290 |
3 | 38593 | 0.285 |
3 | 110000 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 50010 | 2 |
0.320 | 45000 | 2 |
0.325 | 50366 | 4 |
0.330 | 125773 | 4 |
0.335 | 10000 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online